Unraveling of a Neutralization Mechanism by Two Human Antibodies against Conserved Epitopes in the Globular Head of H5 Hemagglutinin
The rapid spread of highly pathogenic avian influenza (HPAI) H5N1 virus underscores the importance of effective antiviral treatment. Previously, we developed human monoclonal antibodies 65C6 and 100F4 that neutralize almost all (sub)clades of HPAI H5N1. The conserved 65C6 epitope was mapped to the globular head of HA. However, neither the 100F4 epitope nor the neutralization mechanism by these antibodies was known. In this study, we determined the 100F4 epitope and unraveled a neutralization mechanism by antibodies 65C6 and 100F4.
I
nfluenza A virus infection is a persistent threat to public health worldwide. High-affinity neutralizing antibodies against conserved epitopes could provide immunity to diverse influenza virus strains and protection against future pandemic viruses. Previously, we developed human monoclonal antibodies (MAb) 65C6 and 100F4 that potently neutralize all H5 clades and subclades of highly pathogenic avian influenza (HPAI) H5N1 viruses except subclade 7.2 ( Fig. 1A) and defined a conformational 65C6 epitope (1) . In this study, we determined the 100F4 epitope and dissected the neutralization mechanism by these antibodies.
To map the 100F4 epitope, a yeast display analysis was carried out similarly to the way we mapped the 65C6 epitope (1, 2) . Figure  1B shows the 15 single amino acid mutations in H5 hemagglutinin (HA) that abolish the binding of antibody 100F4. Among these, the 7 residues at positions 68,112, 137, 143, 251, 254, and 255 were on the HA surface, while the rest were underneath the surface.
To test whether these 7 surface mutations would affect neutralization by antibody 100F4, genes encoding 7 full-length H5 HA single mutants derived from H5N1 strain A/Beijing/01/03 subclade 7.1 were constructed and used to generate H5N1 pseudotypes. The resistance of H5N1 pseudotypes to antibody 100F4 was measured with the pseudotype-based neutralization assay (3) . Compared to the wild-type subclade 7.1 H5N1 pseudotype, only H5N1 pseudotypes expressing H5 HA mutants with mutations at position 68 or 112 (72 or 116 according to H3 numbering) were dramatically resistant to antibody 100F4 ( Fig. 1C and D) . On the HA surface, these two resistant residues are adjacent to each other (Fig. 1E ), but they are next to the Cb in H1 HA and site E in H3 HA (4-7) (Fig. 1F and G) . The 100F4 epitope does not overlap any known epitopes in the head region detected by human and mouse MAb ( Fig. 1H and I) . Thus, the 100F4 epitope is a new conserved conformational epitope on the globular head and away from the receptor binding site (RBS). In contrast, the 65C6 epitope partially overlaps with Sa in H1 HA at residue 161 (K165 according to H3 numbering) and with site A in H3 HA at residues 118 and 121 (T122 and F125 according to H3 numbering) (4) (5) (6) (7) . In addition, the 65C6 epitope also partially overlaps epitopes detected by some human MAb, i.e., FLA5.10 at P118 (P122 according to H3 numbering), FLD21.140 at S121, Y164, and T167 (S125, Y168, and T171 according to H3 numbering) (8) , AVFLuigG01 at P118, Y164, and T167 (P122, Y168, and T171 according to H3 numbering) (9) (Fig. 1H) , and mouse MAb NR2728 at S121 (S125 according to H3 numbering) (10) (Fig. 1I ). In addition, the binding of antibodies 100F4 and 65C6 to their epitopes is also different. Single mutations at position 68 or 112 almost or completely abolish the neutralization by antibody 100F4 (Fig. 1C) , whereas single mutations at positions 118, 121, 161, 164, and 167 only show 3-to 5-fold reductions in neutralization by antibody 65C6 (1).
This could explain why after 2 rounds of antibody-driven mutagenesis (11), escape mutants from antibody 100F4 were readily detected, whereas even after 12 rounds of antibody-driven mutagenesis, no escape mutants from antibody 65C6 were detected ( Fig. 2A) . Sequencing of escape mutants purified by plaque assay revealed the same Asp-to-Ala mutation at position 68 in both escape mutants (Fig. 2B ). Sequence alignment shows that at position 68, all strains tested have an identical Asp residue, whereas at position 112, only subclade 7.2 has a Lys residue, while other clades and subclades have a Glu residue, which explains why 100F4 neutralizes all H5 clades and subclades except subclade 7.2 (1) (Fig. 1A and 2C ).
What could be their neutralization mechanism, since both of the conserved epitopes 65C6 and 100F4 are present in the head region outside the RBS? To determine the mechanism, we first carried out pseudotype-based neutralization, attachment, postattachment, and fusion assays (12, 13) using five antibodies, PG16, 65C6, 100F4, F10, and AVFluIg03 (AVIg03). Antibody PG16 recognizes HIV-1 gp120 and was used as a negative control (14) . Antibody AVFluIg03, an anti-H5 HA human antibody, recognizes the RBS of the HA head and blocks virus attachment to cells (15) . Antibody F10 recognizes a conserved epitope in the stalk region that blocks virus-cell fusion but not virus attachment to cells (16) .
As shown by the data in Figure 3A , all four anti-HA antibodies but not antibody PG16 exhibited dose-dependent neutralization against H5N1 viruses. In the attachment assay, antibody AVIg03 but not antibodies F10 and PG16 dramatically inhibited virus attachment to the cell targets, whereas antibody 65C6 exhibited low but measurable inhibition of virus attachment and antibody 100F4 did not have any inhibition at all (Fig. 3B ). In the postattachment assay, antibodies AVIg03 and PG16 had minimal effects on postattachment events of virus infection, whereas both antibody 65C6 and 100F4, like antibody F10, dramatically inhibited postattachment events of virus infection (Fig. 3C) .
To determine whether antibodies 65C6 and 100F4 block lowpH-triggered, HA-mediated fusion, we transfected a plasmid expressing H5 HA into HeLa cells using a lentiviral vector (17) . A , as follows: Ca1, cyan; Ca2, light green; Cb, magenta; Sa, forest green; and Sb, orange. Yellow, overlap amino acid residues between the 65C6 epitope and the Sa site. (G) 100F4 and 65C6 epitopes in the context of known neutralization epitopes in H3 HA structure (PBD structure accession number 2VIU), as follows: site A, forest green; site B, orange; site C, yellow-green; site D, cyan; and site E, magenta. Yellow, overlap amino acid residues between the 65C6 epitope and site A. (H) 100F4 and 65C6 epitopes in the context of known neutralization epitopes detected by human MAb in H5 HA structure (PBD structure accession number 2ibx). Neutralization epitopes detected by human MAb are highlighted in forest green, and amino acid residues that overlap amino acid residues of the 65C6 epitope are highlighted in yellow. (I) 100F4 and 65C6 epitopes in the context of known neutralization epitopes detected by mouse MAb in H5 HA structure (PBD structure accession number 2ibx). Neutralization epitopes detected by mouse MAb are highlighted in forest green, and amino acid residues that overlap amino acid residues of 65C6 epitope are highlighted in yellow.
fusion assay was performed as described previously (16, 18) . The results in Figure 3D show that both antibody 65C6 and 100F4, like antibody F10, dramatically inhibited low-pH-triggered, HA-mediated fusion in a dose-dependent fashion. To quantify the fusion data shown in Figure 3D , each image was divided into four areas. The numbers of cells and nuclei in each area were counted manually. The fusion percentage was calculated with the following formula: (number of nuclei Ϫ number of cells)/number of nuclei. For each dose of a given antibody, the mean and standard deviation of the fusion percentages were then calculated. Clearly, like antibody F10, antibodies 65C6 and 100F4 also block low-pH-triggered, HA-mediated fusion in a dose-dependent manner. At and above 1 g/ml, they significantly block fusion compared to the results for control antibody PG16 (all P Ͻ 0.001) (Fig. 3E) . These four experiments have been repeated three times with similar results. Thus, consistent with the epitope-mapping study, antibody 100F4 recognizes an epitope that is totally away from the RBS, and its binding to the epitope does not interfere with virus attachment to the receptor but blocks low-pH-triggered, HA-mediated fusion, while antibody 65C6 recognizes an epitope that is outside but nearby the RBS (1), and its binding to the epitope has low but measurable spatial hindrance of virus attachment to the receptor but blocks postattachment and low-pH-triggered, HA-mediated fusion much more dramatically.
To determine whether the antibodies could block the internalization of viruses, we incubated antibody 100F4 at 37°C for 1 h with three different viruses, A/WSN/33 (H1N1), A/Shenzhen/ 406H/06 (H5N1), and the 100F4 escape mutant A (Fig. 2B, escape  A) , and then added the mixture onto CHO-K1 cells and incubated them at 4°C for 1 h. After two washes with PBS to remove unbound viruses and antibodies, the temperature was rapidly elevated to 37°C to initiate infection. At 2, 40, and 360 min postin- fection, the cells were rinsed extensively, fixed, and stained with mouse anti-influenza NP MAb (Millipore) followed by Alexa 555-conjugated goat anti-mouse IgG antibody (Molecular Probes) and CF488-conjugated goat anti-human IgG antibody (Sigma). Fluorescence images of the viruses and antibodies at 2, 40, and 360 min postinfection are shown in Figure 4A . These images show that adding antibody 100F4 alone onto CHO-K1 cells resulted in no antibody detected either on the cell surface or inside the cells, as for the no-virus and no-antibody controls, whereas adding antibody 100F4 with A/Shenzhen/406H/06 and escape A resulted in antibody mainly detected on the cell surface at 2 min postinfection and in the perinuclear region at 40 min postinfection (Fig. 4A, first and fourth columns), indicating that after antibody 100F4 binding to A/Shenzhen/406H/06 and escape A, the virus and antibody complex still could bind to the HA receptor and be internalized, like the unbounded viruses. Moreover, at 2 min postinfection, all three viruses were mainly detected on the cell surface and very few viruses were internalized, regardless of whether viruses were bound or not bound with antibody 100F4 (Fig. 4A , second column). In contrast, at 40 min postinfection, significant viral transport toward the perinuclear region was observed, similar to what was reported by Lakadamyali et al. (19) , regardless of whether viruses were bound or not bound with antibody 100F4 (Fig. 4A , fifth column). Furthermore, at 360 min postinfection, significant amounts of viral NP were observed in the cytosol and nuclei in cells infected with A/WSN/33 (H1N1), A/Shenzhen/406H/06 (H5N1), and escape A without antibody 100F4 or in cells infected with A/WSN/33 (H1N1) and escape A with antibody 100F4 but not in cells infected with A/Shenzhen/406H/06 (H5N1) with antibody 100F4 (Fig. 4A, seventh column) . To quantify the colocalization between NP and antibody 100F4, the Pearson's correlation coefficient was analyzed using the JACoP plugin in FIJI software (20) and calculated to obtain an unbiased evaluation of the extent of colocalization between them. The coefficients were significantly higher in A/Shenzhen/406H/06 with antibody 100F4 (P Ͻ 0.001) and in escape A with antibody 100F4 (P Ͻ 0.001) than in the A/WSN/33 control with antibody 100F4 at 2 and 40 min postinfection (Fig. 4B) . Similar patterns of internalization and colocalization were also observed with antibody 65C6 (M. R. Qian, H. X. Hu, and P. Zhou, data not shown).
Finally, to determine whether antibodies 65C6 and 100F4 could block low-pH-triggered, HA-mediated fusion mediated by escape A of H5 HA, we transiently transfected plasmids expressing the wild-type and escape A of H5 HA into HeLa cells using Lipofectamine plus (Invitrogen) (17) . The fusion assay was performed as described above. Both antibody 65C6 and 100F4 but not the PG16 control inhibited low-pH-triggered fusion mediated by wild-type H5 HA in a dose-dependent fashion (Fig. 4C) , whereas only antibody 65C6 but not antibodies 100F4 and PG16 inhibited low-pH-triggered fusion mediated by escape A of H5 HA in a dose-dependent fashion (Fig. 4D) . Thus, taking these results together with the confocal image data shown in Figure 4A , we conclude that although antibody 100F4 can still bind escape A of H5 HA and internalize with it into the perinuclear region, antibody 100F4 no longer blocks low-pH-triggered fusion mediated by escape A of H5 HA.
In summary, we unraveled a neutralization mechanism by antibodies 65C6 and 100F4 that differs from two other well-known mechanisms (21), i.e., antibodies that recognize the RBS and block binding of virus to receptors (12, (22) (23) (24) (25) (26) (27) (28) and antibodies that recognize the fusion domain of HA2 and block HA-mediated viruscell membrane fusion (16, 18, 22, (29) (30) (31) (32) (33) (34) (35) (36) (37) . Both antibody 65C6 and 100F4 recognize epitopes outside the RBS and bind virus before and after virus attaches to target cells, similar to the mouse MAbs described by Edwards and Dimmock (13) . Antibody-bound viruses are internalized into the perinuclear region. However, antibody-bound wild-type H5 HA on the virion surface fails to mediate low-pH-triggered membrane fusion, whereas antibody-bound escape A of H5 HA still does.
